Jin J, et al. - Researchers analyzed evidence from randomized controlled trials (RCTs) and observational studies to explore how in adult patients treated with dialysis are affected by β-blocker therapy. They analyzed three RCTs and nine observational studies that were eligible and were identified from MEDLINE, EMBASE, and the Cochrane library from inception to May 2018. In dialysis patients, β-blockers were found to be significantly related to reduced all-cause mortality, cardiovascular mortality, cardiovascular events, or hospitalizations. For patients with dialysis, all-cause mortality significantly differed between β-blocker and no β-blocker therapy, while there was no difference in cardiovascular mortality, or cardiovascular events in observational studies. Overall, β-blockers seemed to be related to attenuated mortality in patients on dialysis.